Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 1/2017

01.01.2017 | Adis Drug Evaluation

Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

verfasst von: Karly P. Garnock-Jones

Erschienen in: Drugs | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and tolerability as a single-dose regimen in the treatment of adult patients with ABSSSI. Single-dose dalbavancin is an effective and generally well tolerated treatment option for adults with ABSSSI, with noninferior efficacy to the two-dose dalbavancin regimen with regard to early clinical response (at 48–72 h) and low rates of adverse events. Clinical success rates at days 14 and 28 also did not significantly differ between the single- and two-dose dalbavancin regimens; neither did clinical success rates at day 14 when analysed by baseline pathogen. It has a broad spectrum of activity against common ABSSSI-related pathogens, and a favourable pharmacokinetic profile allowing for the convenience of single-dose administration. Thus, dalbavancin presents a promising alternative to conventional antibacterials for the treatment of ABSSSI in adult patients.
Literatur
1.
Juul JJ, Mullins CF, Peppard WJ, et al. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin. Ther Clin Risk Manag. 2016;12:225–32.PubMedPubMedCentral
2.
Leuthner KD, Buechler KA, Kogan D, et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–40.CrossRefPubMedPubMedCentral
3.
Van Bambeke F. Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review. Drugs. 2015;75(18):2073–95.CrossRefPubMed
4.
5.
European Medicines Agency. Xydalba® (dalbavancin powder for concentrate for solution for infusion): EU summary of product characteristics. 2016. http://​www.​ema.​europa.​eu. Accessed 11 Nov 2016.
6.
Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–79.CrossRefPubMed
7.
Scott LJ. Dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(11):1281–91.CrossRefPubMed
8.
9.
Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859–86.CrossRefPubMed
10.
11.
Lin G, Credito K, Ednie LM, et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother. 2005;49(2):770–2.CrossRefPubMedPubMedCentral
12.
Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother. 2005;55(Suppl 2):ii21–4.
13.
Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940–5.CrossRefPubMedPubMedCentral
14.
Streit JM, Fritsche TR, Sader HS, et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004;48(2):137–43.CrossRefPubMed
15.
Biedenbach DJ, Bell JM, Sader HS, et al. Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260–3.CrossRefPubMedPubMedCentral
16.
Jones RN, Farrell DJ, Flamm RK, et al. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis. 2015;82(1):73–7.CrossRefPubMed
17.
Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304–7.CrossRefPubMed
18.
Jones RN, Flamm RK, Sader HS. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis. 2013;76(1):122–3.CrossRefPubMed
19.
Karlowsky JA, Adam HJ, Poutanen SM, et al. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis. 2011;69(3):342–7.CrossRefPubMed
20.
Huband MD, Castanheira M, Farrell DJ, et al. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013). Int J Antimicrob Agents. 2016;47(6):495–9.CrossRefPubMed
21.
Mendes RE, Castanheira M, Farrell DJ, et al. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13). J Antimicrob Chemother. 2016;71(1):276–8.CrossRefPubMed
22.
Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–51.CrossRefPubMed
23.
Dunne M, Boucher H, Wilcox MH, et al. Microbiologic analysis of target pathogens identified in the dalbavancin DISCOVER program [abstract no. 1338]. In: Infectious Diseases Week. 2013.
24.
Klinker KP, Borgert SJ. Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther. 2015;37(12):2619–36.CrossRefPubMed
25.
Johnson DM, Fritsche TR, Sader HS, et al. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 2006;27(6):557–60.CrossRefPubMed
26.
Koeth LM, DiFranco-Fisher JM, Dunne M, et al. Dalbavancin and azithromycin synergy/antagonism study by checkerboard MIC [abstract no. D-877]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
27.
28.
Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicob Chemother. 2006;58(4):802–5.CrossRef
29.
Bhavnani SM, Hammel JP, Rubino CM, et al. Pharmacokinetic–pharmacodynamic (PK–PD) analyses for the efficacy of dalbavancin (DAL) using phase 3 data from patients with acute bacterial skin and skin structure infections (ABSSSI) [abstract no. A-1186]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
30.
Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2015;45(4):393–8.CrossRefPubMed
31.
Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicob Chemother. 2007;60(3):681–4.CrossRef
32.
Scoble PJ, Owens RC Jr, Puttagunta S. Pharmacokinetics, safety, and tolerability of a single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy Japanese subjects. Clin Drug Investig. 2015;35(12):785–93.CrossRefPubMedPubMedCentral
33.
34.
Tran MC, Naumovski S, Goldstein EJ. The times they are a-changin’: new antibacterials for skin and skin structure infections. Am J Clin Dermatol. 2015;16(3):137–46.CrossRefPubMed
35.
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–52.CrossRefPubMed
36.
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.CrossRefPubMed
37.
38.
European Medicines Agency. Orbactiv® (oritavancin 400 mg powder for concentrate for solution for infusion): EU summary of product characteristics. 2016. http://​www.​ema.​europa.​eu. Accessed 29 Aug 2016.
39.
European Medicines Agency. EMA assessment report for Xydalba® (dalbavancin powder for concentrate for solution for infusion). EMA/39820/2015. 2015. http://​www.​ema.​europa.​eu. Accessed 2 Nov 2016.
40.
Syed YY, Scott LJ. Oritavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(16):1891–902.CrossRefPubMed
41.
Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials. Stat Med. 2010;29(27):2769–80.CrossRefPubMed
42.
Pollack CV Jr, Amin A, Ford WT Jr, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508–19.CrossRefPubMed
Metadaten
Titel
Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections
verfasst von
Karly P. Garnock-Jones
Publikationsdatum
01.01.2017
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 1/2017
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0666-0

Weitere Artikel der Ausgabe 1/2017

Drugs 1/2017 Zur Ausgabe

Review Article

Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer’s Disease

Leading Article

Engaging Natural Killer T Cells as ‘Universal Helpers’ for Vaccination

Systematic Review

Topiramate in the Treatment of Generalized Convulsive Status Epilepticus in Adults: A Systematic Review with Individual Patient Data Analysis

Adis Drug Evaluation

Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia

Adis Drug Evaluation

Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B

AdisInsight Report

Olaratumab: First Global Approval